Key result
Lorundrostat reduces SBP up to ~14 mmHg in uncontrolled hypertension but consistently elevates hyperkalemia risk.
Why the study?
Multiple systematic reviews and meta-analyses of lorundrostat reported markedly variable effect sizes for blood pressure and hyperkalemia risk despite drawing from identical trials.
Does lorundrostat reduce blood pressure in adults with uncontrolled hypertension?
Systematic Review (n=10)
Does lorundrostat reduce blood pressure in adults with uncontrolled hypertension?
Lorundrostat produces modest blood pressure reductions in uncontrolled hypertension but is consistently associated with an elevated risk of hyperkalemia, though current evidence is limited by methodological heterogeneity.
Answers are grounded in this paper and cite their sources.
Highlights how analytical choices drive divergent BP estimates for lorundrostat; challenges reliance on single meta-analyses and urges standardized methods.
Background Lorundrostat has emerged as a promising therapy for uncontrolled and/or resistant hypertension, with multiple systematic reviews and meta-analyses (SRMAs) evaluating its blood pressure effects and hyperkalemia risk. Despite drawing from identical trials, reported effect sizes varied markedly, warranting an umbrella review. Methods Conducted per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD420261358169), this umbrella review included SRMAs of lorundrostat in adults with uncontrolled hypertension. Pooled estimates for systolic blood pressure (SBP), diastolic blood pressure (DBP), and hyperkalemia risk were extracted and compared. Methodological quality was assessed using A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR-2), and primary study overlap was quantified via corrected covered area (CCA). Results Ten SRMAs were included; seven focused exclusively on lorundrostat, all showing complete overlap (CCA = 100%). Despite this, substantial variability in pooled estimates was observed. Office SBP reductions ranged from − 7.35 to − 13.55 mmHg (the 95% confidence interval [CI] ranged between − 28.57 and 1.47), 24-h ambulatory SBP ranged from − 5.65 to − 7.45 mmHg (the 95% CI ranged between − 13.60 and 2.31), and DBP reductions were relatively consistent at approximately − 3 to − 4 mmHg, but with the 95% CI ranging between − 7.93 and 0.61. Variability stemmed primarily from differences in dose handling, outcome definitions, and analytical approaches. Lorundrostat was consistently associated with elevated hyperkalemia risk (RR 3.19–11.63), though severity was rarely stratified. Methodological quality was predominantly low to critically low. Conclusion Lorundrostat produces a modest blood pressure reduction in uncontrolled hypertension. Current evidence is constrained by methodological heterogeneity, limited long-term data, and inadequate safety reporting. Standardized analytical approaches and greater transparency are essential. The proposed effect size concordance index (ECI) may complement overlap metrics by capturing agreement in effect magnitude and precision; however, further validation is required.
No takes yet. Share an insight, caveat, or question.
Elariny et al. (2026) conducted a systematic review in uncontrolled hypertension (n=10). Lorundrostat was evaluated on Office systolic blood pressure (SBP) reduction (MD -7.35 to -13.55 mmHg, 95% CI -28.57 to 1.47). Lorundrostat produces modest office SBP reductions in uncontrolled hypertension, but is consistently associated with elevated hyperkalemia risk.
Synapse has enriched 10 related papers. Consider them for comparative context: